Overview

Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

Status:
Completed
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral glucocorticosteroid in patients with refractory Behçet's uveitis (BDU). Half of the participants will receive IFNα2a while the other half will receive CsA.
Phase:
Phase 3
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Cyclosporine
Cyclosporins
Interferon alpha-2
Interferon-alpha
Interferons